NDA 018810 · Thepharmanetwork LLC
Thermazene
Silver Sulfadiazine · Topical · Sulfonamide Antibacterial
Last checked: Nov 20, 2026Latest source record: Aug 11, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1985
Dec 23, 1985
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
51
7 Phase 3, 3 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Silver Sulfadiazine" as an intervention, any sponsor and status, largest first.
- Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in CirrhosisPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT05071716 · 524 participants · Start Apr 7, 2022 · Primary completion Dec 23, 2025
Drug: Rifaximin SSD; Placebo · For: Hepatic Encephalopathy
Sites: Dothan, Alabama; Chandler, Arizona; Peoria, Arizona · 150 sites in all
- Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With CirrhosisPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT05297448 · 517 participants · Start Aug 3, 2022 · Primary completion Feb 24, 2026
Drug: Rifaximin SSD; Placebo · For: Hepatic Encephalopathy
Sites: Homewood, Alabama; Chandler, Arizona; Sun City, Arizona · 188 sites in all
- Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver CirrhosisPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT01904409 · 420 participants · Start Jun 2013 · Primary completion Jun 2015
Drug: Placebo; Rifaximin SSD 40 mg IR tablet and 4 more · For: Liver Cirrhosis
Sites: Birmingham, Alabama; Dothan, Alabama; Mobile, Alabama · 120 sites in all
- Comparison of Topical Antibiotics Versus Systemic Antibiotics in Preventing Burn Wound Infection in Pediatric Burn PatientsPivotal-lookingNot yet recruiting
abdul mateenAcademic, hospital or other
NCT07870239 · 222 participants (planned) · Start Nov 5, 2026 · Primary completion May 5, 2027
Drug: Silver Sulfadiazine Cream 1%; Amoxicillin and clavulanate · For: Burn
Sites: Lahore, Pakistan
- Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control GroupTerminated
Mylan Inc.Industry
NCT00634166 · 220 participants · Start Sep 2007 · Primary completion Dec 2013
Drug: Sulfamylon® For 5 % Topical Solution; Topical Antimicrobial/Antifungal Medications · For: Burns
Sites: Mobile, Alabama; Redlands, California; Gainesville, Florida · 9 sites in all
- Pelvic External Combined With 252-Cf Neutron Intracavitary Radiotherapy With or Without Platinum in Treating Advanced Cervical CancerPivotal-lookingStatus unknown
Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityAcademic, hospital or other
NCT02835404 · 200 participants (planned) · Start Nov 2012 · Primary completion Jun 2017
Drug: Nedaplatin · For: Cervical Cancer; Complications
Sites: Chongqing, China
- Mepitel Film Treatment for the Prevention and Cutaneous Toxicity Due to RadiotherapyPivotal-lookingCompleted
Dario ValcarenghiAcademic, hospital or other
NCT02741258 · 164 participants · Start Oct 1, 2015 · Primary completion Dec 31, 2021
Drug: skin cream · For: Post-surgery Radiotherapy
Sites: Bellinzona, Switzerland; Zurich, Switzerland
- Mepilex Ag Versus Silver Sulfadiazine in Children and Adults With Burn Injuries.Pivotal-lookingCompleted
Molnlycke Health Care ABIndustry
NCT01439074 · 162 participants · Start Sep 2011 · Primary completion Sep 2013
Drug: Silver Sulphadiazine Ag cream · For: Burn Injuries
Sites: Guangdong, China; Guangzhou, China; Zhenzhou, China · 9 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effects of Aloe vera on Burn Injuries: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Huang YN, Chen KC, Wang JH, et al. · J Burn Care Res 2024 · Systematic Review, Meta-Analysis
- Antiseptics for burns.
Norman G, Christie J, Liu Z, et al. · Cochrane Database Syst Rev 2017 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Burns (minor thermal).
Wasiak J, Cleland H · BMJ Clin Evid 2009 · Systematic Review
- Peceleganan Spray for the Treatment of Skin Wound Infections: A Randomized Clinical Trial.
Wei Y, Li Y, Li X, et al. · JAMA Netw Open 2024 · Randomized Controlled Trial, Multicenter Study
- Effects of topical insulin on second-degree burn wound healing: brief report.
da Silveira VF, Gomes Silva JL, Lima MHM, et al. · Wound Manag Prev 2024 · Clinical Trial, Research Support, Non-U.S. Gov't
- Honey as a topical treatment for wounds.
Jull AB, Cullum N, Dumville JC, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Thepharmanetwork LLC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.